search
Back to results

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor

Primary Purpose

Rheumatoid Arthritis

Status
Completed
Phase
Phase 3
Locations
Germany
Study Type
Interventional
Intervention
rituximab [MabThera]
Sponsored by
Hoffmann-La Roche
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rheumatoid Arthritis

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • adult patients, 18-75 years of age;
  • rheumatoid arthritis for >=6 months;
  • previous inadequate response to a single anti-TNF alpha inhibitor;
  • methotrexate at a stable dose range 7.5-25 mg/week.

Exclusion Criteria:

  • other chronic inflammatory articular disease or systemic autoimmune disease;
  • previous treatment with MabThera or intolerance to MabThera;
  • corticosteroids>=10 mg/day prednisolone within last 2 weeks, or corticosteroids at unstable doses within last 2 weeks;

Sites / Locations

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

MabThera (Rituximab)

Arm Description

Outcomes

Primary Outcome Measures

Change From Baseline to Week 24 in Disease Activity Score Based on 28-Joint Count (DAS28)
The DAS28 consists of swollen joint count (SJC) and tender joint count (TJC) measurements, the erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and the Patient's Global Assessment of Disease Activity (participant-ated rheumatoid arthritis [RA] activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 greater than (>)3.2 to 5.1 = moderate to high disease activity.

Secondary Outcome Measures

DAS28 Score
The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant-rated RA assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.
Percentage of Participants With European League Against Rheumatism (EULAR) Response of Good or Moderate
The DAS28-based EULAR response criteria were used to measure individual responses as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders experienced a change from baseline of >1.2 with a DAS28 score ≤3.2 and moderate responders experienced a change from baseline >1.2 with DAS28 >3.2 to ≤5.1 or a change from baseline >0.6 to ≤1.2 with a DAS28 score of ≤5.1.
Percentage of Participants With Low Disease Activity (DAS28 ≤3.2) at Week 24
Percentage of participants with low disease activity defined as DAS28 ≤3.2 at follow-up Week 24. The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity).
Percentage of Participants Achieving Remission (DAS28 <2.6) at Week 24
Percentage of participants with remission defined as DAS28 <2.6 at follow-up Week 24. The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.
Percentage of Participants Achieving a Response By EULAR Category
Percentage of participants achieving a response by EULAR category, including 'moderate', 'good', or no response at follow-up Weeks 8, 16, and 24. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline >1.2 with a DAS28 score ≤ 3.2; moderate responders had a change from baseline >1.2 with a DAS28 score of >3.2 to ≤5.1 or a change from baseline >0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders had a change from baseline ≤0.6 or change from baseline >0.6 and ≤1.2 with a DAS28 score of >5.1.
Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
The HAQ-DI score consists of questions referring to 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific sub-category items. The standard disability score was calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do).
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score
The FACIT fatigue scale is base on a 13-item questionnaire to assess the therapy-induced fatigue. Participants were requested to score each question on a scale ranging from 0 (best) to 4 (worst). The scoring system of the FACIT fatigue scale adds up to a total scale ranging from 0 (best) to 52 (worst). The assessment was originally developed for chronic illnesses and is now validated for patients with rheumatoid arthritis (RA). The questionnaire was provided in a German translation.
Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS)
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.
SF-36 Domain Scores
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to two distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.
Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%), 50% or 70% Response (ACR20/ACR50/ACR70)
ACR20/50/70 response: ≥20%, ≥50%, or ≥70% improvement, respectively, in tender or swollen joint counts and ≥20%, ≥50%, or ≥70% improvement, respectively, in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Patient's Global Assessment of Disease Activity, 3) Patient's Assessment of Pain, 4) participant assessment of functional disability via a HAQ-DI, and 5) C-reactive protein or ESR at each visit.
Swollen Joint Count (SJC)
The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of swollen joints, each, ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.
Tender Joint Count (TJC)
The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.
Physician's Global Assessment of Disease Activity
Physicians assessed the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity).
Patient's Assessment of Disease Activity
Participants were to assess the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity).
Patient's Assessment of Pain
Participants were to assess their current level of pain on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand (100 mm) as "unbearable pain".
C-Reactive Protein (CRP)
Mean CRP as measured as an acute phase reactant by mg per deciliter (mg/dL) at screening, Days 1 and 15, and Weeks 8, 16, and 24.
Erythrocyte Sedimentation Rate (ESR)
Mean ESR, as an acute phase reactant, measured in mm/hr at screening, Days 1 and 15, and Weeks 8, 16, and 24.
Rheumatoid Factor (RF)
Mean RF as measured by international unit per milliliter (IU/mL) at screening and Weeks 8, 16, and 24.

Full Information

First Posted
March 4, 2014
Last Updated
June 30, 2016
Sponsor
Hoffmann-La Roche
search

1. Study Identification

Unique Protocol Identification Number
NCT02079532
Brief Title
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor
Official Title
An Open-label Study to Evaluate the Safety of MabThera, and Its Effect on Treatment Response, in Patients With Rheumatoid Arthritis Following Inadequate Response to a Single Anti-TNF Agent
Study Type
Interventional

2. Study Status

Record Verification Date
June 2016
Overall Recruitment Status
Completed
Study Start Date
November 2006 (undefined)
Primary Completion Date
November 2010 (Actual)
Study Completion Date
November 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche

4. Oversight

5. Study Description

Brief Summary
This study will evaluate the efficacy and safety of MabThera in patients with active rheumatoid arthritis who have had an inadequate response to one prior anti-TNF alpha inhibitor. MabThera-naive patients will be stratified into 3 arms, according to previous inadequate response to a)etanercept, b)infliximab or c)adalimumab. Patients will be treated with MabThera (1g infusion) on day 1 and day 15, and will continue their basic methotrexate therapy. The anticipated time on study treatment is 2+ years, and the target sample size is 100-500 individuals.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
302 (Actual)

8. Arms, Groups, and Interventions

Arm Title
MabThera (Rituximab)
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
rituximab [MabThera]
Intervention Description
1 g was given by intravenous infusion on Days 1 and 15
Primary Outcome Measure Information:
Title
Change From Baseline to Week 24 in Disease Activity Score Based on 28-Joint Count (DAS28)
Description
The DAS28 consists of swollen joint count (SJC) and tender joint count (TJC) measurements, the erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and the Patient's Global Assessment of Disease Activity (participant-ated rheumatoid arthritis [RA] activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 greater than (>)3.2 to 5.1 = moderate to high disease activity.
Time Frame
Week 24
Secondary Outcome Measure Information:
Title
DAS28 Score
Description
The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant-rated RA assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.
Time Frame
Screening and Weeks 8, 16, and 24
Title
Percentage of Participants With European League Against Rheumatism (EULAR) Response of Good or Moderate
Description
The DAS28-based EULAR response criteria were used to measure individual responses as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders experienced a change from baseline of >1.2 with a DAS28 score ≤3.2 and moderate responders experienced a change from baseline >1.2 with DAS28 >3.2 to ≤5.1 or a change from baseline >0.6 to ≤1.2 with a DAS28 score of ≤5.1.
Time Frame
Weeks 8, 16, and 24
Title
Percentage of Participants With Low Disease Activity (DAS28 ≤3.2) at Week 24
Description
Percentage of participants with low disease activity defined as DAS28 ≤3.2 at follow-up Week 24. The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity).
Time Frame
Week 24
Title
Percentage of Participants Achieving Remission (DAS28 <2.6) at Week 24
Description
Percentage of participants with remission defined as DAS28 <2.6 at follow-up Week 24. The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.
Time Frame
Week 24
Title
Percentage of Participants Achieving a Response By EULAR Category
Description
Percentage of participants achieving a response by EULAR category, including 'moderate', 'good', or no response at follow-up Weeks 8, 16, and 24. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline >1.2 with a DAS28 score ≤ 3.2; moderate responders had a change from baseline >1.2 with a DAS28 score of >3.2 to ≤5.1 or a change from baseline >0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders had a change from baseline ≤0.6 or change from baseline >0.6 and ≤1.2 with a DAS28 score of >5.1.
Time Frame
Weeks 8, 16, and 24
Title
Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
Description
The HAQ-DI score consists of questions referring to 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific sub-category items. The standard disability score was calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do).
Time Frame
Screening and Weeks 8, 16, and 24
Title
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score
Description
The FACIT fatigue scale is base on a 13-item questionnaire to assess the therapy-induced fatigue. Participants were requested to score each question on a scale ranging from 0 (best) to 4 (worst). The scoring system of the FACIT fatigue scale adds up to a total scale ranging from 0 (best) to 52 (worst). The assessment was originally developed for chronic illnesses and is now validated for patients with rheumatoid arthritis (RA). The questionnaire was provided in a German translation.
Time Frame
Screening and Weeks 8, 16, and 24
Title
Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS)
Description
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.
Time Frame
Screening and Weeks 8, 16, and 24
Title
SF-36 Domain Scores
Description
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to two distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.
Time Frame
Screening and Weeks 8, 16, and 24
Title
Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%), 50% or 70% Response (ACR20/ACR50/ACR70)
Description
ACR20/50/70 response: ≥20%, ≥50%, or ≥70% improvement, respectively, in tender or swollen joint counts and ≥20%, ≥50%, or ≥70% improvement, respectively, in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Patient's Global Assessment of Disease Activity, 3) Patient's Assessment of Pain, 4) participant assessment of functional disability via a HAQ-DI, and 5) C-reactive protein or ESR at each visit.
Time Frame
Weeks 8, 16, and 24
Title
Swollen Joint Count (SJC)
Description
The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of swollen joints, each, ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.
Time Frame
Screening and Weeks 8, 16, and 24
Title
Tender Joint Count (TJC)
Description
The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.
Time Frame
Screening and Weeks 8, 16, and 24
Title
Physician's Global Assessment of Disease Activity
Description
Physicians assessed the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity).
Time Frame
Screening and Weeks 8, 16, and 24
Title
Patient's Assessment of Disease Activity
Description
Participants were to assess the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity).
Time Frame
Screening and Weeks 8, 16, and 24
Title
Patient's Assessment of Pain
Description
Participants were to assess their current level of pain on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand (100 mm) as "unbearable pain".
Time Frame
Screening and Weeks 8, 16, and 24
Title
C-Reactive Protein (CRP)
Description
Mean CRP as measured as an acute phase reactant by mg per deciliter (mg/dL) at screening, Days 1 and 15, and Weeks 8, 16, and 24.
Time Frame
Screening, Days 1 and 15, and Weeks 8, 16, and 24
Title
Erythrocyte Sedimentation Rate (ESR)
Description
Mean ESR, as an acute phase reactant, measured in mm/hr at screening, Days 1 and 15, and Weeks 8, 16, and 24.
Time Frame
Screening, Days 1 and 15, and Weeks 8, 16, and 24
Title
Rheumatoid Factor (RF)
Description
Mean RF as measured by international unit per milliliter (IU/mL) at screening and Weeks 8, 16, and 24.
Time Frame
Screening and Weeks 8, 16, and 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: adult patients, 18-75 years of age; rheumatoid arthritis for >=6 months; previous inadequate response to a single anti-TNF alpha inhibitor; methotrexate at a stable dose range 7.5-25 mg/week. Exclusion Criteria: other chronic inflammatory articular disease or systemic autoimmune disease; previous treatment with MabThera or intolerance to MabThera; corticosteroids>=10 mg/day prednisolone within last 2 weeks, or corticosteroids at unstable doses within last 2 weeks;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Chair
Facility Information:
City
Bad Abbach
ZIP/Postal Code
93077
Country
Germany
City
Bad Aibling
ZIP/Postal Code
83043
Country
Germany
City
Bad Bramstedt
ZIP/Postal Code
24576
Country
Germany
City
Bamberg
ZIP/Postal Code
96047
Country
Germany
City
Berlin
ZIP/Postal Code
10117
Country
Germany
City
Berlin
ZIP/Postal Code
12200
Country
Germany
City
Berlin
ZIP/Postal Code
13055
Country
Germany
City
Berlin
ZIP/Postal Code
13125
Country
Germany
City
Berlin
ZIP/Postal Code
13589
Country
Germany
City
Berlin
ZIP/Postal Code
14163
Country
Germany
City
Bonn
ZIP/Postal Code
53111
Country
Germany
City
Bremen
ZIP/Postal Code
28199
Country
Germany
City
Cuxhaven
ZIP/Postal Code
27476
Country
Germany
City
Damp
ZIP/Postal Code
24351
Country
Germany
City
Donaueschingen
ZIP/Postal Code
78166
Country
Germany
City
Dresden
ZIP/Postal Code
01109
Country
Germany
City
Düsseldorf
ZIP/Postal Code
40211
Country
Germany
City
Düsseldorf
ZIP/Postal Code
40225
Country
Germany
City
Erfurt
ZIP/Postal Code
99096
Country
Germany
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
City
Erlangen
ZIP/Postal Code
91056
Country
Germany
City
Essen
ZIP/Postal Code
45239
Country
Germany
City
Essen
ZIP/Postal Code
45326
Country
Germany
City
Frankfurt Am Main
ZIP/Postal Code
60590
Country
Germany
City
Freiburg
ZIP/Postal Code
79106
Country
Germany
City
Fulda
ZIP/Postal Code
36039
Country
Germany
City
GIEßEN
ZIP/Postal Code
35392
Country
Germany
City
Gommern
ZIP/Postal Code
39245
Country
Germany
City
Göttingen
ZIP/Postal Code
37075
Country
Germany
City
Hagen
ZIP/Postal Code
58135
Country
Germany
City
Halle
ZIP/Postal Code
06120
Country
Germany
City
Hamburg
ZIP/Postal Code
22081
Country
Germany
City
Hannover
ZIP/Postal Code
30159
Country
Germany
City
Hannover
ZIP/Postal Code
30625
Country
Germany
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
City
Herne
ZIP/Postal Code
44652
Country
Germany
City
Hofheim
ZIP/Postal Code
65719
Country
Germany
City
Homburg/saar
ZIP/Postal Code
66424
Country
Germany
City
Jena
ZIP/Postal Code
07743
Country
Germany
City
Karlsruhe
ZIP/Postal Code
76135
Country
Germany
City
Köln
ZIP/Postal Code
50924
Country
Germany
City
Ludwigshafen
ZIP/Postal Code
67063
Country
Germany
City
Mainz
ZIP/Postal Code
55122
Country
Germany
City
Mainz
ZIP/Postal Code
55131
Country
Germany
City
Mittelherwigsdorf
ZIP/Postal Code
02763
Country
Germany
City
Muenchen
ZIP/Postal Code
80336
Country
Germany
City
Mönchengladbach
ZIP/Postal Code
41061
Country
Germany
City
München
ZIP/Postal Code
80335
Country
Germany
City
München
ZIP/Postal Code
81541
Country
Germany
City
Münster
ZIP/Postal Code
48149
Country
Germany
City
Naunhof
ZIP/Postal Code
04683
Country
Germany
City
Oldenburg
ZIP/Postal Code
26121
Country
Germany
City
Osnabrück
ZIP/Postal Code
49074
Country
Germany
City
Pirna
ZIP/Postal Code
01796
Country
Germany
City
Ratingen
ZIP/Postal Code
40882
Country
Germany
City
Rostock
ZIP/Postal Code
18059
Country
Germany
City
Schwerte
ZIP/Postal Code
58239
Country
Germany
City
Sendenhorst
ZIP/Postal Code
48324
Country
Germany
City
Stuttgart
ZIP/Postal Code
70178
Country
Germany
City
Treuenbrietzen
ZIP/Postal Code
14929
Country
Germany
City
Trier
ZIP/Postal Code
54292
Country
Germany
City
Tübingen
ZIP/Postal Code
72076
Country
Germany
City
ULM
ZIP/Postal Code
89081
Country
Germany
City
Wiesbaden
ZIP/Postal Code
65189
Country
Germany
City
Wiesbaden
ZIP/Postal Code
65191
Country
Germany
City
Wuerzburg
ZIP/Postal Code
97080
Country
Germany
City
Wuppertal
ZIP/Postal Code
42105
Country
Germany
City
Würselen
ZIP/Postal Code
52146
Country
Germany
City
Zeven
ZIP/Postal Code
27404
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor

We'll reach out to this number within 24 hrs